Cellceutix Plans Clinical Trial in Patients With Ulcerative Proctitis
January 26, 2015 07:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - Jan 26, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology...
Cellceutix Phase 2b Clinical Trial of Brilacidin Accepted for Oral Presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
January 22, 2015 07:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - Jan 22, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology...
Cellceutix Reports Spleen Lesion 'Disappears' in Patient With Metastatic Stage 4 Ovarian Cancer in Clinical Trial of Anti-Cancer Drug Kevetrin
January 20, 2015 07:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - Jan 20, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology...
Cellceutix Invites All to Attend Company's Live Webcast of Presentation at Biotech Showcase 2015 Today at 2:00 PM PT (5:00 PM ET)
January 12, 2015 07:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - Jan 12, 2015) - Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Releases Confidence Interval Statistics Showing Clinical Success Rates for Brilacidin in Treatment of ABSSSI
January 05, 2015 07:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - Jan 5, 2015) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Adds Dr. Daniel Jorgensen as Chief Medical Officer
December 29, 2014 07:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - Dec 29, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Reports Positive Results of Brilacidin in Microbiological Intent-to-Treat Population in Phase 2b ABSSSI Trial; Additional Pharmacokinetic Information to Be Submitted
December 22, 2014 07:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - Dec 22, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix: Prurisol(TM) for Psoriasis -- FDA Agrees That Phase 2 Study May Begin
December 10, 2014 07:39 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - Dec 10, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Antibiotic Brilacidin Receives QIDP Designation From FDA
December 08, 2014 07:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - Dec 8, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix: December to Be Momentous Month in Company's History
November 24, 2014 07:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - Nov 24, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...